Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/ refractory indolent lymphoma

Chan Yoon Cheah, Loretta J. Nastoupil, Sattva S. Neelapu, Sheryl G. Forbes, Yasuhiro Oki, Nathan H. Fowler

Research output: Contribution to journalLetterpeer-review

84 Scopus citations
Original languageEnglish (US)
Pages (from-to)3357-3359
Number of pages3
JournalBlood
Volume125
Issue number21
DOIs
StatePublished - 2015

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

MD Anderson CCSG core facilities

  • Clinical Trials Office

Cite this